Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922837 | 0.83 | NOS1 (0.36) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL15681459 | 0.83 | NOS1 (0.36) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL14593924 | 0.81 | CA1 (0.38) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL19889516 | 0.79 | CA1 (0.36) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL6740260 | 0.79 | CA1 (0.37) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL110481 | 0.79 | CA1 (0.37) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL12309460 | 0.79 | CA1 (0.37) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL12567766 | 0.79 | CA1 (0.37) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL16665545 | 0.79 | CA1 (0.37) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL6740257 | 0.79 | CA1 (0.37) | CA1CA2CA7NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115651130-A | Core-shell structure flame retardant, preparation method and application thereof in preparation of low smoke density material | 万华化学（宁波）有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-112266500-B | Marking powder, preparation method and application thereof, high-rigidity PC alloy suitable for laser marking and preparation method thereof | 万华化学(四川)有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-118994049-B | Synthesis method of ceftazidime side chain ethyl ester | 山东金城医药化工有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-118994049-A | Synthesis method of ceftazidime side chain ethyl ester | 山东金城医药化工有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-110234320-B | Composition comprising at least one pharmaceutically acceptable salt of eprofibrate dissolved in an aqueous medium and having improved intestinal absorption | 纳什制药公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-115651130-A | Core-shell structure flame retardant, preparation method and application thereof in preparation of low smoke density material | 万华化学（宁波）有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-112266500-B | Marking powder, preparation method and application thereof, high-rigidity PC alloy suitable for laser marking and preparation method thereof | 万华化学(四川)有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11185520-B2 | Composition comprising at least one water-soluble pharmaceutically acceptable salt of elafibranor having improved intestinal absorption | NASHPHARM (FR) | 2021-11-30 | — | — | US | disclosed |
| CN-112266500-A | Marking powder, preparation method and application thereof, high-rigidity PC alloy suitable for laser marking and preparation method thereof | 万华化学(四川)有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-20190274982-A1 | COMPOSITION COMPRISING AT LEAST ONE WATER-SOLUBLE PHARMACEUTICALLY ACCEPTABLE SALT OF ELAFIBRANOR HAVING IMPROVED INTESTINAL ABSORPTION | NASHPHARM (FR) | 2019-09-12 | — | — | US | disclosed |
| EP-3518916-A1 | COMPOSITION COMPRISING AT LEAST ONE WATER-SOLUBLE PHARMACEUTICALLY ACCEPTABLE SALT OF ELAFIBRANOR HAVING IMPROVED INTESTINAL ABSORPTION | Nashpharm (FR) | 2019-08-07 | — | — | EP | disclosed |
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | DUAN JINGWU (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1263756-B1 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1335908-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002038553-A2 | TRIAZOLE DERIVATIVES AND THEIR USE AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001027077-A2 | HYDROXYSULFONYLALKYLENE-, PHOSPHONOALKYLENE- OR DIFLUORO(PHOSPHONONON)METHYL- SUBSTITUTED BENZENE, OR BENZOFURAN DERIVATIVES AS NON-PEPTIDIC CDC25 INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | TNF, XPNPEP1, MMP2 | CA1 286/4885CA2 1611/4885CA7 1492/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | CA1 278/4885CA2 1446/4885CA7 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.